Roche Pharmaceutical Development and Sales Overview

Perjeta Global sales CHFbn CER growth +5% Regional sales CER growth US +1% 3.5 3.0 Europe -16% 2.5 2.0 Japan -1% 1.5 1.0 International +33% 0.5 0.0 YTD Sep 19 YTD Sep 20 YTD Sep 21 YTD Sep 22 YTD Sep 2022 sales of CHF 3,090m • US: Cannibalization from Phesgo • ● EU: Cannibalization from Phesgo International: Accelerated growth in all regions (LATAM, APAC, EEMEA) CER=Constant Exchange Rates Roche 152

View entire presentation